In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive — and covered an exclusive trip for leaders to attend last summer’s ...

(The Hill) – A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli ...

(The Hill) – A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro.

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from ...

The move comes less than two weeks after the Food and Drug Administration declared an end to the shortage of semaglutide, the active ingredient in Wegovy as well as diabetes drug Ozempic.

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...